Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Characterization of a bone biorepository: Comparison of bone metastases from breast, prostate, renal, lung cancers, and myeloma.
Cancer Angiogenesis and Metastases
2018 ASCO Annual Meeting
J Clin Oncol 36, 2018 (suppl; abstr e24019)
Author(s): Kerith Ruoyao Wang, John A. Abraham, Peter McCue, Matthew Joseph Schiewer, Karen Marie Bussard, Alessandro Fatatis, Lucia Languino, Benjamin Leiby, Raymond O'Neill, Jianhong Li, Benjamin I. Richter, William Kevin Kelly; Thomas Jefferson University, Philadelphia, PA; Thomas Jefferson University Hospital, Philadelphia, PA; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Drexel University, Philadelphia, PA; Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA, US
Background: While bone is one of the most common sites of metastasis for many cancer types, lack of access to the necessary quantity and quality of human specimens limits the understanding of the bone microenvironment. Therefore, our multidisciplinary team has developed a method of intraoperative rapid retrieval of human bone tissue and blood as well as collection of matching primary tissue and clinical data. Methods: Bone Biorepository Bank (BBB) is notified when patients (pts) with primary or metastatic cancer to the bone with standard of care surgeries are identified and consented. Biospecimens are processed within minutes and stored as FFPE blocks, preserved in RNAlater, and snap frozen. Plasma and buffy coat are extracted from whole blood. H&E sections are reviewed by Pathology for tumor burden (TB), presence of tumor necrosis (TN), osteoblastic and osteoclastic activity level (OBC), and fibrous stromal proliferation level (SP). Primary tumor slides are obtained, and clinical information is extracted from medical records. Results: From Dec 2016 to Dec 2017 BBB enrolled 55 pts with 63 bone, 47 blood, and 26 primary samples. The bank includes 16 cancer types with the largest sample amounts in breast (N = 22), prostate (18), renal (14) myeloma (13), and lung (8) out of 96 FFPE blocks. 75.3% samples had systemic treatment (tx) before surgery. Preliminary analysis of H&Es in the 5 largest cancer types revealed no differences in TB or TN. There was significant difference in OBC (p = 0.0047); in pairwise comparisons renal had significantly lower OBC compared to OBC in breast (0.039), myeloma (0.0072), and prostate (0.0089). SP also had statistical significance (0.0037); pairwise comparisons showed that SP was significantly higher in breast compared to SP in renal (0.0093) and myeloma (0.0035). Analysis of pts who were tx naïve versus pts who received tx showed no histological difference. Conclusions: Specimen analysis showed more similarities than differences in histological patterns regardless of tx status and cancer type. Continued growth of BBB will be an invaluable resource to better understand the metastatic bone microenvironment. Additional molecular and genetic tests are ongoing.
2. First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.